SkinBioTherapeutics PLC SkinBioTherapeutics to Present at Investor Evening
19 June 2017 - 6:00PM
RNS Non-Regulatory
TIDMSBTX
SkinBioTherapeutics PLC
19 June 2017
SkinBioTherapeutics plc
SkinBioTherapeutics to Present at Investor Evening
Manchester, UK - 19 June 2017 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, is pleased to announce that Dr Catherine O'Neill (CEO) will
be presenting at an investor evening held in London, EC4 hosted by
Turner Pope Investments (TPI) Ltd.
The event will be held on Thursday 29(th) June and will commence
at 5pm.
To register your interest, please email info@turnerpope.com or
call 0203 621 4121.
Ends
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Catherine O'Neill, 2760
CEO
Douglas Quinn, CFO
Turner Pope Investments Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / 2020
Alex Shaw / Deborah Bell SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXKNFSEXEEF
(END) Dow Jones Newswires
June 19, 2017 04:00 ET (08:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024